Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will release its second quarter 2026 financial results before the market opens on Friday, August 7, 2026. Management will host a webcast conference call at 8:30 a.m. ET, accessible via live audio webcast on the company’s website, with a replay available afterward.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings date | Neutral | +1.2% | Scheduled Q1 2026 results after market close with management webcast afterward |
| Feb 24 | Earnings date | Neutral | +6.3% | Scheduled Q4 and full-year 2025 results before market open with webcast |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-date announcements historically had positive 24-hour reactions, while RPID was down 1.9% before this headline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2026 financial results prior to the market open on Friday, August 7, 2026.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 7, 2026. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com